Y., Pollak, M., Azoulay, L
FDA approval represents far more than a regulatory formality
Effects of GLP-1s on these disorders are not well established, and could theoretically reduce or exacerbate symptoms in different circumstances
Thus, in line with mixed findings on the potential of medication targeting ghrelin to induce changes in body weight (Gupta et al., 2021), the current body of evidence shows limited convergence for ghrelin increasing reward responses in obesity
Telehealth works well for the monthly monitoring visits GLP-1 treatment requires, and multiple Texas-licensed platforms serve Fort Worth patients with medication delivery
This combination yields approximately 1.5kg fat loss monthly per 2024 meta-analyses